Subject: Trials Scheduled for 3TC, To Test AIDS-Virus Effect
Date: Published: 3/24/93 (25 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Business Brief -- BioChem Pharma Inc.:
    Trials Scheduled for 3TC,
    To Test AIDS-Virus Effect

    BioChem Pharma Inc. said clinical trials will begin next month in
 the U. S. and seven other countries to test the efficacy of 3TC in
 patients infected with human immunodeficiency virus, or HIV.  
    Like other anti-HIV drugs, 3TC is a nucleoside analogue, which
 interferes with the replication of the virus that causes AIDS.  
    A spokeswoman for the Canadian unit of Britain's Glaxo Holdings
 PLC, which is developing the drug under an agreement with BioChem,
 described the tests as "early Phase Two-Three" trials.  She said
 Glaxo hopes to complete the tests by the end of this year and then
 broaden the trials.  BioChem, a Montreal-based biotechnology company,
 discovered 3TC and signed an agreement with Glaxo covering
 commercialization of the drug.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]